Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well tivantinib works in treating patients with recurrent or
metastatic breast cancer. Tivantinib may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth.